Does Sinapic Acid Provide Neuroprotection Against Cisplatin-Induced Toxicity in HT-22 Cells
Dosyalar
Tarih
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
Özet
Introduction: This study aimed to explain the beneficial effects and possible protective mechanisms of SA against cisplatin-induced oxido-inflammatory damage in HT-22 rat hippocampal cells by biochemical and molecular methods. Materials and Methods: Primarily, different concentrations of Sinapic acid (SA) (100, 400 and 800 µM) were applied to HT-22 cells under in vitro conditions before cisplatin application in order to produce neuroprotective activity. Half an hour after the SA application, 5.5 µM cisplatin was applied to all wells except the control group and incubated for 24 hours under appropriate conditions. Cell viability was determined with routinely used 3-(4,5-Dimethyl Thiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and cytotoxic activity was determined by lactate dehydrogenase (LDH) assays. Oxidative stress was evaluated by total antioxidant capacity (TAC), Catalase (CAT), glutathione reductase (GSH), malondialdehyde (MDA) and superoxide dismutase (SOD) assays. In addition, the effect of SA on Caspase-3 gene regulation in HT-22 cells was investigated by Real-Time PCR. Results: Cisplatin decreased cell viability by approximately 40% and increased LDH level in HT-22 cells. In SA administered groups, cell viability increased and LDH level decreased regardless of dose. SA showed its neuroprotective effect by stopping the cytotoxic activity of cisplatin and increasing its antioxidant action mechanism in cells. Similarly, caspase-3 up-regulated by cisplatin approached the control value with SA administration. SA abolished the neurotoxicity of cisplatin and significantly reduced cell death and Oxidative stress levels. Conclusion: These findings show that SA protects HT-22 cells against cisplatin by preventing both oxidative stress formation mechanisms and apoptosis induction of cells. © 2023, Yuzuncu Yil Universitesi Tip Fakultesi. All rights reserved.












